Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.
Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University
Advertisement
Articles by Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University
Advertisement
Latest Updated Articles
Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLCPublished: January 14th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5